On November 8, 2024, Aimed Alliance submitted feedback to the Maryland Prescription Drug Affordability Board regarding its updated rules for policy review, final actions, upper payment limits (UPLs), and hearing procedures.
In it’s comment, Aimed Alliance urged the Board to adopt a patient-centered approach in the policy review process, consider a ban on copay accumulators when reviewing potential policy solutions, and avoid using discriminatory cost-effectiveness measures when setting UPLs. Additionally, the feedback recommended that the Board assume responsibility for UPL monitoring rather than placing the burden on patients and requested the removal of authority for the chair or staff designee to limit repetitious testimony from speakers. Read the comment here.
.
Last Updated on November 22, 2024 by Aimed Alliance
